Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

BDX · Q2 2026 Earnings

Becton Dickinson

Reported May 7, 2026

30-second summary

SENTIMENT: Constructive BD delivered Q2 revenue of $4.71B (+5.2% reported, +2.6% FXN) and adjusted EPS of $2.90, beating the $2.72–$2.82 prior-quarter guide by $0.08 at the high end. Adjusted operating margin was 24.2% (down 110bps YoY on ~160bps of tariff impact), and management raised FY26 adjusted EPS by $0.07 at the midpoint to $12.52–$12.72 while reaffirming low-single-digit FXN revenue growth, the ~25% adjusted operating margin, and the 16–17% adjusted tax rate. The GAAP loss of $37M and 2.0% GAAP operating margin reflect ~$450M of non-cash asset impairment charges tied to Excellence Unleashed exit actions across all segments, plus separation-related items — not a deterioration in the underlying margin profile.

Headline numbers

EPS

Q2 FY2026

$2.90

Revenue

Q2 FY2026

$4.71B

+5.2% YoY

Gross margin

Q2 FY2026

45.7%

Operating margin

Q2 FY2026

2.0%

Key financials

Q2 FY2026

Metric	Q2 FY2026	YoY	Q1 FY2026	QoQ
Revenue	$4.71B	+5.2%	$5.25B	-10.2%
EPS	$2.90	—	$2.91	-0.3%
Gross margin	45.7%	—	46.0%	-27bps
Operating margin	2.0%	—	10.5%	-854bps

Guidance

Company raised full-year adjusted EPS guidance and reaffirmed revenue growth while withdrawing several non-core guidance metrics; Q2 beat EPS expectations.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS	Q2 FY2026	$2.72 to $2.82	$2.90	+$0.08-$0.18 above guide	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS	FY2026	$12.35 to $12.65	$12.52 to $12.72	+$0.07 at midpoint (+0.6%)	Raised
Adjusted Operating Margin	FY2026	approximately 25%	Withdrawn — no replacement	—	Withdrawn
Interest and Other Net	FY2026	$600 to $620 million	Withdrawn — no replacement	—	Withdrawn
Adjusted Effective Tax Rate	FY2026	16% to 17%	Withdrawn — no replacement	—	Withdrawn
Weighted Shares Outstanding	FY2026	approximately 282 million shares	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Revenue Growth (FXN) (Low single-digit), GAAP Revenue Growth (Low single-digit plus)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
Medical Essentials	$1.647B	+4.7%
Connected Care	$1.12B	+4.9%
BioPharma Systems	$0.59B	+2.5%
Interventional	$1.357B	+7.3%
Revenue Growth (FXN)	2.6%	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
United States	$2.917B	+5.1%
International	$1.797B	+5.5%
Adjusted Diluted EPS	$2.90	—
Operating Income	$93 million	—
Gross Margin	45.7%	—
Accelerated Share Repurchase	$2.0 billion	—
Debt Retired	$2.1 billion	—

Management tone

Narrative arc: Q3 "executing through headwinds" → Q4 "clear-the-table FY26 reset" → Q1 "pure-play med tech reinvention" → Q2 "headwinds quantified, buybacks prioritized over M&A"

Capital allocation moved from balanced-to-aggressive in Q1 to explicit valuation conviction this quarter. In Q1 management committed to the $2B ASR and $2B debt paydown as a near-term execution item; this quarter both are done and management went further, stating that buybacks are now the top form of value creation given perceived undervaluation. The anchor: "At the current stock price...we have a top priority on buying back shares as we do that as a top form of value creation for our shareholders...we do have an active M&A pipeline. But we...are prioritizing towards share buybacks at the current valuation levels." This is the most direct statement of valuation conviction in this coverage window and is a meaningful posture change — M&A was the primary growth lever in Q3 and Q4 FY25, secondary in Q1, and is now explicitly subordinated.

The Alaris/vaccines/China headwind narrative is now framed as contained and on-plan rather than open-ended. Management called these out as "less than 10% of revenue" being "managed with discipline" and noted that vaccines comps ease in H2 as the segment laps the Q2 FY25 onset. Alaris specifically delivered ~50bps of share gain in the quarter and ~150bps year-to-date, with the largest competitive funnel in company history — a shift from defensive language a year ago to active share-gain framing.

BD Excellence completed its arc from manufacturing tool to enterprise operating system. Q3 FY25 framed it as a margin flywheel; Q4 added the $200M cost-out; Q1 extended it into commercial via the new CRO role; this quarter management described dedicated BD Excellence staff embedded in R&D and selling organizations, with >2,000 Kaizans planned and 8% productivity delivered in Q2. The anchor: "By expanding BD excellence into commercial and R&D, we're building a stronger operating system." The $200M cost-out program is at a $150M run rate with full delivery expected by end of next year. The signal is that BD now treats operational discipline as a distributed capability rather than a project — consistent with a low-growth company leaning harder on internal levers.

GLP-1 framing strengthened as a multi-leg story. Management called out two new next-generation GLP-1 program wins in BioPharma Systems and stated biologics are now expected to represent ~55% of segment revenue, "reinforcing our confidence in the long-term growth outlook for this business." This helps explain why management is comfortable maintaining the FY26 framework despite continued vaccines pressure on the same segment.

Oil and resin cost pressure was introduced as a new explicit risk factor with a stated mitigation roadmap. The exposure is ~5% of COGS with hedging covering current-year impact; BD Excellence productivity, multiple resin sources, and pricing actions were called out as ongoing levers. The mitigation language paired with the reaffirmed ~25% adjusted operating margin signals management is comfortable absorbing the exposure within the existing framework.

Recurring themes management leaned on this quarter:

Scaled growth platforms (biologics, APM, PureWIC, advanced tissue regeneration) accelerating and becoming material to portfolio mixBD Excellence productivity (8% in Q2) now embedded enterprise-wide across operations, commercial, and R&D with >2,000 Kaizans plannedNew BD strategy execution delivering 'broad-based' performance with 90% of portfolio in mid-single-digit growth despite known headwindsCapital allocation shift toward shareholder returns via buybacks at perceived undervaluation, maintaining disciplined tuck-in M&AQuantified path to headwind mitigation: Alaris 200bp headwind in FY27, clearing by FY28; vaccines and China pressure easing but no structural recovery assumedInnovation pipeline increasingly concentrated in higher-growth, higher-margin categories with organic R&D fueling next-gen launches FY26-FY27

Risks management surfaced:

FDA warning letter on ChloroPrep/PurePrep El Paso facility (mitigation: 3-week testing window before resumption; confidence high given European product track record)Oil and resin price inflation (5% of COGS); hedging programs cover ~50% of North America resins but tail risk into FY27 if prices remain elevatedChina market dynamics expected to persist; BD revenue exposure dropping from 4% toward 3% as portfolio grows but 'challenging dynamics' acknowledgedVaccines demand collapse sustainability; management unclear if second-year headwind repeats at same scale; monitoring pharma partner orders for visibilityAlaris comparison headwind 200bp in FY27; remediation completed FY26 but lapping the large upgrade cycle creates structured headwind before recovery in FY28

Answers to last quarter's watch list

Q2 revenue growth holding at or above ~2% — Q2 grew +2.6% FXN and +5.2% reported, clearing the bar set last quarter. The FY low-single-digit FXN guide was reaffirmed and management said H2 will be "roughly similar" to H1, closing the door definitively on any back-half acceleration narrative.

Resolved positively

Waters transaction close and ASR execution — $2.0B ASR executed and $2.1B of debt retired in the quarter. The FY27 EPS rebase math is now the relevant variable, but Q2 execution proceeded on schedule.

Resolved positively

Adjusted effective tax rate holding at 16–17% — reaffirmed at 16–17% on the print.

Resolved positively

Life Sciences trajectory ahead of separation — Life Sciences is no longer disclosed as a continuing segment in the new "New BD" reporting structure following the Waters close on Feb 9, 2026; BioPharma Systems (-1.8% FXN) is the closest analog within continuing operations. The original watch is no longer comparable because the reporting structure changed.

Not resolved

Connected Care and BD Interventional sustaining 5%+ FXN growth — Interventional posted +5.3% FXN (vs +5.8% FXN in Q1), slight decel but holding the bar. Connected Care posted +3.2% FXN (vs +4.7% FXN in Q1), below the watch threshold on an FXN basis. Interventional borderline-positive; Connected Care below threshold on FXN.

Continue monitoring

What to watch into next quarter

Adjusted operating margin progression toward the reaffirmed ~25% FY target: Q2 came in at 24.2% with 160bps of tariff drag; the H2 ramp depends on BD Excellence productivity and easier vaccines comps. Watch for the H2 trajectory implied by Q3 actuals.

Q3 FY26 revenue growth vs Q3 FY25 baseline of $5.51B: management said H2 will be "roughly similar" to H1's +2.6% FXN, implying Q3 revenue of roughly $5.45–$5.55B reported (with ~120bps FX tailwind). A miss against this implied band would force another FY revenue cut.

ChloroPrep/PurePrep El Paso resumption: management cited a 3-week testing window before resuming shipments. Watch for confirmation of resumption and any quantified revenue impact from the disruption.

Connected Care FXN growth re-accelerating: this quarter's +3.2% FXN dropped below the prior 5% watch threshold. A further decel in Q3 would put pressure on the New BD growth algorithm.

Buyback pace following the $2.0B ASR: management explicitly prioritized buybacks over M&A at current valuation. Incremental repurchase announcements on the Q3 call would confirm the posture shift; an M&A pivot would signal valuation conviction softening.

Sources

BDX Q2 FY2026 press release (filed 2026-05-07): https://www.sec.gov/Archives/edgar/data/10795/000162828026031638/ex9913312026.htm
BDX Q2 FY2026 earnings call commentary (prepared remarks and management discussion)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.